Another USP7 inhibitor, PTL, reported by Li et al. in 2020, demonstrates the potential to inhibit CRC progression by targeting USP7 activity and Wnt/β-catenin protein signaling [42]. The gene discussed is USP7; the disease is colorectal carcinoma.